GC-072, a Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens
Abstract
Burkholderia pseudomallei, the etiological agent of melioidosis, is a Gram-negative bacterium with additional concern as a biothreat pathogen. The mortality rate fromB. pseudomalleivaries depending on the type of infection and extent of available health care; in the case of septicemia, left untreated, it can range from 50% to 90%. Current therapy for melioidosis is biphasic, consisting of parenteral acute-phase treatment for 2 weeks or longer, followed by oral eradication-phase treatment lasting several months.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 01, 2019
- Source ID
- 10.1128/aac.00834-19
Entities
People
- Anthony M. Treston
- Arnold Louie
- Christine M. Butler
- George L. Drusano
- Henry S. Heine
- Herbert P Schweizer
- Jeffry D. Shearer
- Kelly L. Warfield
- Michelle L. Saylor
- Steven D. Zumbrun
- Sunisa Chirakul
Organizations
- Defense Threat Reduction Agency
- Emergent BioSolutions
- United States Army Medical Research Institute of Infectious Diseases
- University of Florida